Reference Detail

Ref Type

PMID

Authors

ST. Durant, KG. Pike, N Colclough, L Riches, A Garcia-Trinidad, T Hunt, S Ling, J Stott, I Barrett, L Zheng, Y Wang, K Chen, T Zhang, VP Reddy, A Sykes, P Johnstrom, G Jones, A Pierce, J Karlin, J Kahn, J Allen, K Valerie, R Illingworth and M Pass

Title

AZD1390, a potent and selective orally bioavailable blood-brain barrier-penetrant ATM inhibitor, radiosensitizes and improves survival of orthotopic glioma and metastatic brain tumor models

Journal	Vol	Issue	Date	Pages	Journal Short Title
Mol Cancer Ther

URL

http://mct.aacrjournals.org/content/17/1_Supplement/A104

Abstract Text

Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A104

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Treatment Approach

Gene Name	Source	Synonyms	Protein Domains	Gene Description	Gene Role

Therapy Name	Drugs	Efficacy Evidence	Clinical Trials
AZD1390	AZD1390	3	5

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description
AZD1390		AZD 1390\|AZD-1390	ATM Inhibitor 13	AZD1390 is a selective inhibitor of ATM that is optimized for blood-brain barrier penetration, thus may preferentially sensitize CNS tumors for radiotherapy (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A104, PMID: 29938225, PMID: 31299316).

Gene	Variant	Impact	Protein Effect	Variant Description	Associated with drug Resistance

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
TP53 mutant	glioblastoma	sensitive	AZD1390	Preclinical - Cell culture	Actionable	In a preclinical study, TP53 mutant glioblastoma cells demonstrated increased sensitivity to radiosensitization by AZD1390 treatment compared to TP53 wild-type cells in culture (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A104).	detail...
ATM positive	glioblastoma	sensitive	AZD1390	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD1390 inhibited Atm activity, sensitized glioblastoma cell lines to radiotherapy in culture, and demonstrated efficacy in mouse models of glioblastoma (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A104).	detail...
ATM positive	lung cancer	sensitive	AZD1390	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD1390 inhibited Atm activity, sensitized lung cancer cells to radiotherapy in culture, and demonstrated efficacy in cell line xenograft models (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A104).	detail...